Cadrenal reports Q2 2026 results, launches partnering process for cardiac pipeline
The company presented late-breaking Phase 2 CAD-1005 data at ISTH and said cash on hand should fund operations into early 2027.
Cadrenal Therapeutics reported second quarter 2026 results on August 13, 2026, and detailed a corporate update on what it calls its Cardiac Acute Critical Care Franchise and a new strategic partnering process, according to the release.
The company said it presented late-breaking Phase 2 data on CAD-1005 at the International Society of Thrombosis and Hemostasis (ISTH) 2026 Congress in Paris, from a randomized, blinded, placebo-controlled study that demonstrated an absolute reduction of more than 25% in thrombotic events when CAD-1005 was added to standard anticoagulant therapy, with a favorable safety profile and renal-protective baseline.1 Cadrenal said it had achieved regulatory guidance on the Phase 3 path for CAD-10051.
On regulatory matters, Cadrenal said it submitted a request to the U.S. Food and Drug Administration on July 8, 2026, for Rare Pediatric Disease Designation for tecarfarin for the prevention of life-threatening blood clots inside coronary artery aneurysms in children with Kawasaki Disease.1
The company said it launched a structured partnering process to explore development, licensing, and commercialization transactions for CAD-1005, frunexian, and tecarfarin, pursuing a capital-efficient model focused on strategic out-licensing, portfolio monetization, and commercial co-development rather than independently funding large late-stage clinical trials.1 It also signed a private placement that generated approximately $3.0 million in gross proceeds, with up to approximately $5.8 million in additional gross proceeds if the associated warrants are exercised in full for cash.1
As of early August 2026, Cadrenal said it had approximately $4.2 million in cash and cash equivalents, which based on its current operating plan the company believes are expected to fund operations through the first quarter of 2027.1 The company added that its existing cash resources are not sufficient to advance its product candidates to clinical trial readiness or to commence and complete any clinical trials, and it does not plan to commence a clinical trial unless funding sufficient to complete that trial is in place.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.